Nasdaq nmra.

Get the latest Neumora Therapeutics Inc (NMRA) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions.Sep 15, 2023 · The shares are expected to begin trading on the Nasdaq Global Select Market on September 15, 2023 under the ticker symbol “NMRA.” US6409791000. Neumora Therapeutics, Inc. is a clinical-stage biotechnology company. It offers a precision medicine approach for brain diseases through the integration of data science and neuroscience. The firm focuses on advancing medicines for therapeutically relevant targets implicated in CNS diseases, targeting novel mechanisms of action ...$8.11 +0.06 +0.75% Find the latest Financials data for Neumora Therapeutics, Inc. Common Stock (NMRA) at Nasdaq.com. The stock is expected to list on the Nasdaq under the ticker symbol “NMRA.” J.P. Morgan, BofA Securities, Guggenheim Securities, RBC Capital Markets and William Blair are the underwriters. The ...

Andrey Tolkachev/iStock via Getty Images. Neumora Therapeutics ( NASDAQ: NMRA) stock dipped 4% in late afternoon trading Friday following a $250M IPO. Shares of the psychiatric drug developer ...Nov 23, 2023 · On Wednesday, Neumora Therapeutics Inc. [NASDAQ: NMRA] rose 1.88% to $11.91. The stock’s lowest price that day was $11.76, but it reached a high of $12.14 in the same session. During the last five days, there has been a drop of approximately -0.83%. Over the course of the year, Neumora Therapeutics Inc. shares have dropped approximately -26.71%. Nov 1, 2023 · Successfully completed initial public offering: In September 2023, Neumora completed its initial public offering of its common stock and shares began trading on the Nasdaq Global Select Market under the ticker symbol “NMRA.” Since its inception, Neumora has raised over $850 million to further its mission to confront the global brain disease ...

NMRA-266 is a highly selective positive allosteric modulator of the M4 muscarinic receptor that Neumora is developing as a treatment for schizophrenia and other neuropsychiatric disorders. “The initiation of this Phase 1 study is an important step in the development of NMRA-266.

The Watertown, MA-based Neumora Therapeutics (NASDAQ:NMRA), a Phase 3 biotech developing therapies for brain diseases has priced its initial public offering of 14.71 million shares of its common ...Sep 28, 2023 · Neumora Therapeutics (NASDAQ: NMRA), a biotech company focused on developing treatments for neurodegenerative diseases such as Alzheimer’s and Parkinson’s, went public on September 15th with ... Neumora Therapeutics, Inc. (NASDAQ: NMRA), a clinical-stage biopharmaceutical company redefining neuroscience drug development, today announced the pricing of its initial public offering of ...Neumora hopes to list its shares on Nasdaq under the symbol NMRA. JP Morgan, BofA Securities, Stifel, Guggenheim Securities, RBC Capital Markets and William Blair are serving a joint bookrunners.

WATERTOWN, Mass., Oct. 30, 2023 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company redefining neuroscience drug development, today announced ...

Fiscal Q3 2023 ended 9/30/23. Get the latest Neumora Therapeutics Inc (NMRA) real-time quote, historical performance, charts, and other financial information to help you make …

Successfully completed initial public offering: In September 2023, Neumora completed its initial public offering of its common stock and shares began trading on the Nasdaq Global Select Market under the ticker symbol “NMRA.” Since its inception, Neumora has raised over $850 million to further its mission to confront the global brain disease ...Victor J. Blue/Bloomberg. Shares of Watertown biotech Neumora Therapeutics retreated 4.4 percent Friday, in the company’s debut on the Nasdaq stock exchange, after it raised $250 million in an ...6 hari yang lalu ... (Nasdaq: NMRA), a clinical-stage biopharmaceutical company redefining neuroscience drug development, today announced that the Company will ...WATERTOWN, Mass., Oct. 10, 2023 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company redefining neuroscience drug ...Neumora (NASDAQ: NMRA) develops precision medicines to restore brain health. It focuses on discovering, developing, and commercializing targeted therapies for people living with brain diseases. The company was founded in …Oct 10, 2023 · Shares of Neumora Therapeutics Inc (NASDAQ:NMRA) were trading lower on Tuesday, a month after the company announced its IPO on the NASDAQ exchange.. RBC Capital Markets On Neumora Therapeutics ...

Based on analysts offering 12 month price targets for NMRA in the last 3 months. The average price target is $ 0.00 with a high estimate of $ 0.00 and a low estimate of $ 0.00 .Neumora Therapeutics Inc (NASDAQ: NMRA) gained 15.4% to $14.00 in pre-market trading. Neumora Therapeutics recently initiated a Phase 1 single ascending dose / multiple ascending dose study of ...Neumora Therapeutics, Inc. (NASDAQ: NMRA), a clinical-stage biopharmaceutical company redefining neuroscience drug development, today announced the pricing of its initial public offering of ...View NMRA historial stock data and compare to other stocks and exchanges. ... Real-time last sale data for U.S. stock quotes reflect trades reported through Nasdaq only.(NASDAQ: NMRA) forecast ROA is N/A, which is lower than the forecast US Biotechnology industry average of -0.21%. What is NMRA's Price Target? According to 5 Wall Street analyst s that have issued a 1 year NMRA price target, the average NMRA price target is $22.00 , with the highest NMRA stock price forecast at $26.00 and the lowest NMRA stock ...

Find the latest Financials data for Neumora Therapeutics, Inc. Common Stock (NMRA) at Nasdaq.com.Nov 27, 2023 · The latest price target for Structure Therapeutics ( NASDAQ: GPCR) was reported by JMP Securities on Monday, November 20, 2023. The analyst firm set a price target for 91.00 expecting GPCR to rise ...

About Robert Lenz, M.D., Ph.D., executive vice president, head of research and development Dr. Rob Lenz is executive vice president, head of research and development at Neumora.Shares of Neumora Therapeutics Inc (NASDAQ:NMRA) were trading lower on Tuesday, a month after the company announced its IPO on the NASDAQ exchange. RBC Capital Markets On Neumora Therapeutics.Neumora Therapeutics, Inc. Common Stock stock price (NMRA) NASDAQ: NMRA. Buying or selling a stock that’s not traded in your local currency? Don’t let the currency conversion trip you up. Convert Neumora Therapeutics, Inc. Common Stock stocks or shares into any currency with our handy tool, and you’ll always know what you’re getting.Atomera Inc (NASDAQ:ATOM)’s traded shares stood at 0.16 million during the last session, with the company’s beta value hitting 1.45. At the close of trading, the stock’s price was $6.97, to imply an increase of 0.29% or $0.02 in intraday trading. The ATOM share’s 52-week high remains $10.72 ...Created with Sketch. when trading, helping you to optimize your price and have a successful order execution. Investors may trade in the Pre-Market (4:00-9:30 a.m. ET) and the After Hours Market (4 ...Home NMRA • NASDAQ Neumora Therapeutics Inc Follow Share $11.92 Nov 24, 5:45:00 PM GMT-5 · USD · NASDAQ · Disclaimer search Compare to Sezzle Inc $10.20 SEZL5.38% WK Kellogg Co $12.15... Nov 22, 2023 · 6 Wall Street analysts have issued 12-month price objectives for Neumora Therapeutics' stock. Their NMRA share price targets range from $18.00 to $26.00. On average, they predict the company's stock price to reach $22.67 in the next year. This suggests a possible upside of 90.3% from the stock's current price.

Neumora Therapeutics is a biotech company located in Massachusetts, United States, which is part of the Healthcare sector, and is traded under the ticker NMRA on the NASDAQ exchange. Neumora Therapeutics stock last closed at $11.69 , down 1.35% from the previous day, and has decreased N/A in one year.

Neumora Therapeutics, Inc. (NASDAQ:NMRA – Get Free Report) shares gapped up before the market opened on Wednesday .The stock had previously closed at $11.69, but opened at $12.14. Neumora ...

Which Neumora Therapeutics insiders have been buying company stock? The following insiders have purchased NMRA shares in the last 24 months: Amgen Inc ($29,999,985.00), Arch Venture Partners Xii, Llc ($2,626,582.57), Henry O Gosebruch ($189,300.00), and Kristina Burow ($28,803,319.17).Neumora Therapeutics, Inc. (NASDAQ:NMRA) shares fell 8% to $11.02. Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO) fell 7.4% to $9.97. BeiGene, Ltd. (NASDAQ:BGNE) fell 7.2% to $193.86. B of A ...Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the ...Shares of Neumora Therapeutics (NMRA 0.41%) were down more than 32% for the week as of Thursday's market close, according to data provided by S&P Global Market Intelligence.WATERTOWN, Mass., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company redefining neuroscience drug development, today announced financial results for the third quarter ended September 30, 2023 and provided a general business update.View live Neumora Therapeutics, Inc. chart to track its stock's price action. Find market predictions, NMRA financials and market news.WATERTOWN, Mass., Oct. 30, 2023 -- Neumora Therapeutics, Inc. , a clinical-stage biopharmaceutical company redefining neuroscience drug development, today announced that the Company will...Neumora Therapeutics, Inc. (NASDAQ:NMRA – Get Free Report) major shareholder Arch Venture Partners Xii, Llc bought 3,357 shares of the company’s stock in a transaction on Tuesday, November 14th.No Data Available. Neumora Therapeutics Inc. Annual stock financials by MarketWatch. View the latest NMRA financial statements, income statements and …Neumora Therapeutics Inc. Common Stock stock price (NMRA) NASDAQ: NMRA. Buying or selling a stock that’s not traded in your local currency? Don’t let the currency conversion trip you up. Convert Neumora Therapeutics Inc. Common Stock stocks or shares into any currency with our handy tool, and you’ll always know what you’re getting.(NASDAQ: NMRA) forecast ROA is N/A, which is lower than the forecast US Biotechnology industry average of -0.21%. What is NMRA's Price Target? According to 5 Wall Street analyst s that have issued a 1 year NMRA price target, the average NMRA price target is $22.00 , with the highest NMRA stock price forecast at $26.00 and the lowest NMRA stock ...Successfully completed initial public offering: In September 2023, Neumora completed its initial public offering of its common stock and shares began trading on the Nasdaq Global Select Market under the ticker symbol “NMRA.” Since its inception, Neumora has raised over $850 million to further its mission to confront the global brain disease ...

Ventyx Biosciences, Inc. (NASDAQ:VTYX) fell 22.1% to $23.38 after the company announced results from the Phase 2 trial of VTX002 in patients with moderate-to-severely active ulcerative colitis.Shares of Neumora Therapeutics Inc (NASDAQ: NMRA) were trading lower on Tuesday, a month after the company announced its IPO on the NASDAQ exchange. RBC Capital Markets On Neumora Therapeutics.According to the issued ratings of 6 analysts in the last year, the consensus rating for Neumora Therapeutics stock is Buy based on the current 6 buy ratings for NMRA. The average twelve-month price prediction for Neumora Therapeutics is $22.67 with a high price target of $26.00 and a low price target of $18.00.Common Stock stock price (NMRA). NASDAQ: NMRA. Buying or selling a stock that's not traded in your local currency? Don't let the currency conversion trip you ...Instagram:https://instagram. should i buy microsoft stockballard powerbest online stock broker for day tradingkbw stock The latest price target for CymaBay Therapeutics ( NASDAQ: CBAY) was reported by UBS on Tuesday, September 26, 2023. The analyst firm set a price target for 25.00 expecting CBAY to rise to within ...About This Event Neumora Therapeutics, Inc. (Nasdaq: NMRA), visits the Nasdaq MarketSite in Times Square. Neumora Therapeutics, Inc. is a clinical-stage biopharmaceutical company founded to ... how much does va dental costjerry williams gold and silver dealer Find the latest news headlines from Neumora Therapeutics, Inc. Common Stock (NMRA) at Nasdaq.com.Nov 27, 2023 · NMRA-266 is an investigational positive allosteric modulator of the M4 muscarinic receptor subtype, a clinically validated target for the treatment of schizophrenia. Neumora exclusively licensed ... best cash out refinance lenders Neumora Therapeutics (NASDAQ: NMRA), a biotech company focused on developing treatments for neurodegenerative diseases such as Alzheimer’s and Parkinson’s, went public on September 15th with ...Oct 10, 2023 · Shares of Neumora Therapeutics Inc (NASDAQ:NMRA) were trading lower on Tuesday, a month after the company announced its IPO on the NASDAQ exchange.. RBC Capital Markets On Neumora Therapeutics ... Created with Sketch. when trading, helping you to optimize your price and have a successful order execution. Investors may trade in the Pre-Market (4:00-9:30 a.m. ET) and the After Hours Market (4 ...